Lakefront Biotherapeutics (LKFT) Long-Term Investments (2020 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Long-Term Investments for 5 consecutive years, with $56.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Long-Term Investments rose 4.9% year-over-year to $56.1 million; the TTM figure through Mar 2026 stood at $56.1 million (up 4.9% YoY), while the FY2025 annual figure was $54.5 million, down 74.53% from the prior year.
• Long-Term Investments climbed to $56.1 million in Q1 2026 per LKFT's latest filing, from $54.5 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $213.9 million in Q4 2024 and bottomed at $14.6 million in Q4 2023.
• Historically, Long-Term Investments has averaged $69.3 million across 4 years, with a median of $54.2 million in 2025.
• Annual changes were most pronounced in 2024 — Long-Term Investments jumped 1364.57% — and 2025, when it plunged 74.53%.
• Lakefront Biotherapeutics' Long-Term Investments stood at $14.6 million in 2023, then surged by 1364.57% to $213.9 million in 2024, then slumped by 74.53% to $54.5 million in 2025, then advanced by 2.99% to $56.1 million in 2026.
• Business Quant data shows LKFT's Long-Term Investments at $56.1 million in Q1 2026, $54.5 million in Q4 2025, and $54.8 million in Q3 2025.